ABUS Projected Dividend Yield
Arbutus Biopharma Corp ( NASDAQ : ABUS )Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. Co. is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. 21 YEAR PERFORMANCE RESULTS |
ABUS Dividend History Detail ABUS Dividend News ABUS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |